Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Rare Occurrence of Secondary CML After AML: Case Study

By: Kayci Reyer
Posted: Friday, November 6, 2020

A case study published in Current Medical Research and Opinion focused on a unique patient with acute myeloid leukemia (AML) who developed secondary chronic myeloid leukemia (CML) after treatment with autologous hematopoietic stem cell transplantation (auto-HSCT). Although AML commonly follows CML, Waiyi Zou, MD, of Sun Yat-sen University in China, and colleagues noted it is rare for CML to be the primary disease.

“The case expands the understanding of secondary CML and emphasizes the importance of oncological vigilance in patients with secondary CML after AML therapy,” the authors commented.

The patient was initially diagnosed with AML subtype M5b at age 34 in 2011. A combination treatment of mitoxantrone, cytarabine, and etoposide was administered for two courses before a regimen of idarubicin, cytarabine, and etoposide was implemented. Cytarabine was also administered as consolidation chemotherapy. Following these treatments, the patient underwent auto-HSCT with prophylactic intrathecal methotrexate cytarabine and dexamethasone, achieving complete remission in 2012.

After 4 years in remission, the patient presented with an elevation in leukocyte count lasting 4 months, prompting a diagnosis of secondary CML. Tyrosine kinase inhibitor therapy was initiated due to the patient’s “severely compromised overall condition.” Imatinib therapy was administered for 18 months. In August 2017, imatinib was replaced by nilotinib. Difficulty controlling the patient’s blood sugar preceded a switch to dasatinib in June 2018. Following this treatment regimen, the patient again achieved remission and has remained in remission at the time the case study was submitted for publication.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.